

## TABLE OF CONTENTS

<u>Chapter</u>		<u>Page</u>
1	<b>INTRODUCTION</b> .....	1-1
	1.1 Background .....	1-1
	1.2 Justification .....	1-4
	1.3 Authority and Confidentiality of Data Collection.....	1-5
	1.4 Study Overview.....	1-6
	1.5 Design Issues.....	1-8
	1.51 Laboratory Sensitivity Regarding CLIA ID Number and Volume of Testing.....	1-8
	1.5.2 Complexity Model Database.....	1-9
	1.5.3 Definition of Test and Test Volume .....	1-9
	1.6 Phase I Enrollment and Field Procedures .....	1-10
	1.6.1 Enrollment.....	1-10
	1.6.2 Field Procedures.....	1-11
	1.7 Phase II.....	1-12
	1.7.1 Advance Letter, Telephone Enrollment, and Data Collection Packet .....	1-13
	1.7.2 Telephone Tabulator Recruitment and Training.....	1-13
	1.7.3 Telephone Tabulation .....	1-14
	1.7.4 Key Entry .....	1-15
	1.8 Statistical Issues .....	1-15
	1.8.1 CLIA ID Number Verification and Problem Resolution .....	1-15
	1.8.2 Clusters within Each Location .....	1-16
	1.8.3 Weighting and Nonresponse Adjustment .....	1-16
	1.8.4 Raking and Calculation of Final Laboratory Weights .....	1-17
	1.9 Phase I Verification and Validation of On-Site Data Collection .....	1-17
	1.9.1 Phase I Telephone Verification .....	1-17
	1.9.2 Phase I Site Validation Visits .....	1-18
	1.10 Phase II Verification and Validation .....	1-18
	1.11 Overall Survey Estimates of Laboratory Volume .....	1-19
	1.12 Issues to be Considered when Interpreting NICLTS Data .....	1-20

## TABLE OF CONTENTS (continued)

<u>Chapter</u>		<u>Page</u>
2	<b>SAMPLE DESIGN</b> .....	2-1
	2.1 Sampling Frame .....	2-1
	2.2 Sample Design Parameters .....	2-3
	2.3 Sample Selection .....	2-3
	2.4 Other Sampling Issues .....	2-9
3	<b>SYSTEMS</b> .....	3-1
	3.1 Phase I-Collection and Processing of Data from Laboratories with Moderate and High Complexity CLIA Certificates .....	3-1
	3.1.1 Tabulation Device .....	3-1
	3.1.2 Data Processing and Data Quality Assurance .....	3-9
	3.2 Phase II-Collection and Processing of Data from Laboratories with Waived and PPM CLIA Certificates .....	3-14
	3.2.1 Data Collection and Entry .....	3-14
	3.2.2 Data Processing .....	3-15
4	<b>OPERATIONS</b> .....	4-1
	4.1 Phase I .....	4-1
	4.1.1 Advance Mailing .....	4-3
	4.1.2 Telephone Enrollment .....	4-3
	4.1.3 Confirmation Letter .....	4-9
	4.1.4 Field Operations .....	4-9
	4.1.5 Field Protocol and Procedures .....	4-17
	4.1.6 Survey Management System Case Management and Reporting.....	4-19
	4.1.7 Telephone Support Lines .....	4-21
	4.2 Phase II .....	4-23
	4.2.1 Advance Mailing .....	4-24
	4.2.2 Telephone Enrollment .....	4-24
	4.2.3 Mailing Operations .....	4-25
	4.2.4 Telephone Data Collection .....	4-28
	4.2.5 Survey Management System Case Management and Reporting .....	4-35
	4.2.6 Laboratory Information and Technical Support Line .....	4-35

## TABLE OF CONTENTS (continued)

<u>Chapter</u>		<u>Page</u>
5	<b>STATISTICAL ISSUES</b> .....	5-1
	5.1 Phase I .....	5-1
	5.1.1 CLIA ID Number Problem Resolution .....	5-1
	5.1.2 Weighting and Nonresponse Adjustments .....	5-2
	5.1.3 Phase I Summary Case Result Reports .....	5-8
	5.2 Phase II .....	5-16
	5.2.1 CLIA ID Number Problem Resolution .....	5-16
	5.2.2 Phase II Summary Case Result Reports .....	5-16
	5.3 Overall Survey Results .....	5-25
6	<b>DATA TABULATION PROTOCOL QUALITY ASSURANCE</b> .....	6-1
	6.1 Phase I Quality Assurance .....	6-1
	6.1.1 Telephone Verification .....	6-1
	6.1.2 Validation .....	6-4
	6.2 Phase II Quality Assurance .....	6-19
	6.2.1 Telephone Tabulation Monitoring .....	6-19
	6.2.2 Field Validation .....	6-20

### List of Tables

<u>Table</u>		<u>Page</u>
2-1	Distribution of laboratories on the sampling frame by region and laboratory group .....	2-2
2-2	Definition of regions .....	2-4
2-3	Definition of laboratory groups .....	2-4
2-4	Definition of application categories .....	2-5
2-5	Distribution of laboratories in the initial sample by region and laboratory group .....	2-6

## TABLE OF CONTENTS (continued)

### List of Tables (continued)

<u>Table</u>		<u>Page</u>
2-6	Distribution of laboratories in the primary sample by region and laboratory group .....	2-7
2-7	Distribution of laboratories in the initial, primary, and reserve samples by stratum .....	2-8
2-8	Distribution of Phase I primary sample by region and laboratory group .....	2-10
2-9	Distribution of Phase I reserve sample by region and laboratory group .....	2-11
2-10	Distribution of waived and PPM laboratories on the OSCAR database by region and laboratory group .....	2-12
2-11	Distribution of Phase II primary sample by region and laboratory group .....	2-13
2-12	Distribution of Phase II reserve sample by region and laboratory group .....	2-14
5-1	Overall response codes and CLIA ID numbers .....	5-3
5-2	Characteristics of daily log nonresponse .....	5-7
5-3	Phase I telephone enrollment results .....	5-9
5-4	Phase I Field Tabulation results .....	5-11
5-5	Phase I Telephone Verification results .....	5-13
5-6	Phase I Validation Telephone Enrollment results .....	5-13
5-7	Phase I Validation Field Tabulation results .....	5-15
5-8	Summary of Phase I response rates .....	5-16
5-9	Phase II Telephone Enrollment results .....	5-17
5-10	Ineligibility, Telephone Enrollment and Field Tabulation stages, Phase I and Phase II .....	5-18
5-11	Phase II Field Tabulation results .....	5-19
5-12	Phase II Validation Telephone Enrollment results .....	5-22

## TABLE OF CONTENTS (continued)

### List of Tables (continued)

<u>Table</u>		<u>Page</u>
5-13	Phase II Validation Field Tabulation results.....	5-24
5-14	Summary of Phase II response rates.....	5-25
5-15	Number of distinct clusters by region and group .....	5-26
5-16	Estimated mean number of distinct clusters per laboratory by region and group .....	5-27
5-17	Estimated volume of tests by region and group (000,000) .....	5-29
5-18	Estimated mean volume per laboratory by region and group .....	5-30
5-19	Estimated distinct clusters and volume by laboratory type .....	5-31
6-1	Summary of analyte counts tabulated during the original survey and the validation survey at 30 Phase I validation locations .....	6-7
6-2	Summary of cluster counts tabulated during the original survey and the validation survey at 30 Phase I validation locations .....	6-10
6-3	Summary of volumes tabulated during the original survey and the validation survey at the 30 Phase I validation locations .....	6-14
6-4	Volumes tabulated during original survey and validation survey at the 30 Phase I validation locations, broken out by tabulator's source of volume data .....	6-18
6-5	Comparison of Phase II validation methods with Phase II primary mail-telephone methods .....	6-24
6-6	Comparison of survey and validation data for Phase II laboratories .....	6-29

### List of Figures

<u>Figure</u>		<u>Page</u>
6-1	Scatter plot of distinct analyte counts tabulated during original survey and validation survey at the 30 Phase I validation locations .....	6-8

**TABLE OF CONTENTS (continued)**

List of Figures (continued)

<u>Figures</u>		<u>Page</u>
6-2	Scatter plot of distinct analyte counts tabulated during original survey and validation survey at the Phase I validation locations with largest laboratory removed .....	6-9
6-3	Scatter plot of distinct cluster counts tabulated during original survey and validation survey at the 30 Phase I validation locations .....	6-12
6-4	Scatter plot of distinct cluster counts tabulated during original survey and validation survey at the Phase I validation locations with largest laboratory removed .....	6-13
6-5	Scatter plot of total volumes tabulated during original survey and validation survey at the 30 Phase I validation locations .....	6-15
6-6	Scatter plot of total volumes tabulated during original survey and validation survey of the Phase I validation locations with largest laboratory removed .....	6-17
6-7	Scatter plot of distinct analyte counts tabulated during original survey and validation survey of the 110 Phase II validation locations .....	6-26
6-8	Scatter plot of distinct cluster counts tabulated during original survey and validation survey at the 110 Phase II validation locations .....	6-28
6-9	Scatter plot of distinct analyte counts tabulated during original survey and validation survey at the 110 Phase II validation locations .....	6-32
6-10	Scatter plot of total volume tabulated during original survey and validation survey at the Phase II validation locations with largest laboratory removed .....	6-33

William J. Rauch, D.A., MT (ASCP)  
Project Director  
Westat  
Health Studies Sector  
1650 Research Boulevard  
Rockville, Maryland 20850  
RAUCHB1@WESTAT.COM

Steven J. Steindel, Ph.D.  
Project Officer  
Center for Disease Control & Prevention  
Williams Building, Room 2722  
2877 Brandywine Road  
Atlanta, Georgia 30341  
SNS6@CDC.GOV